Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 10/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899942 | 0.90 | SCN9A (0.42) | SCN9AHDAC1HDAC8HDAC6SCN5A | |
| SCHEMBL2276096 | 0.88 | SCN9A (0.44) | SCN9AHDAC1HDAC8HDAC6SCN5A | |
| SCHEMBL1260037 | 0.86 | SCN9A (0.45) | SCN9AHDAC1HDAC8HDAC6SCN5A | |
| SCHEMBL13662214 | 0.85 | SCN9A (0.43) | SCN9ASCN5ADRD3 | |
| SCHEMBL1260642 | 0.85 | SCN9A (0.46) | SCN9AHDAC1HDAC8HDAC6SCN5A | |
| SCHEMBL900238 | 0.83 | SCN9A (0.41) | SCN9AHDAC1HDAC8HDAC6SCN5A | |
| SCHEMBL1981364 | 0.83 | SCN9A (0.41) | SCN9AHDAC1HDAC8HDAC6SCN5A | |
| SCHEMBL13286194 | 0.82 | MEN1 (0.36) | SCN9AHDAC1HDAC8HDAC6SCN5A | |
| SCHEMBL6368381 | 0.81 | SCN9A (0.48) | SCN9ACYP3A4CYP2C19 | |
| SCHEMBL15294528 | 0.81 | ESR1 (0.41) | SCN9AHDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140057928-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-20130288957-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20130261050-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUB-POPULATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| US-20130261134-A1 | MESYLATE SALT FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| EP-2530082-A1 | Process for preparing 2, 3-disubstituted indoles | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20120135949-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20120122887-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| US-7851625-B2 | Process for preparing 2,3-disubstituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-14 | — | — | US | disclosed |
| US-7642352-B2 | Process for preparing 2,3-disubstituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| US-20090264655-A1 | PROCESS FOR PREPARING 2,3-DISUBSTITUTED INDOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264655-A1 | PROCESS FOR PREPARING 2,3-DISUBSTITUTED INDOLES | DCLK2, DCLK1, TTL | SCN9A 2090/4885HDAC1 1997/4885HDAC8 3772/4885 |
| US-20120122887-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | SCN9A 829/4885HDAC1 289/4885HDAC8 1251/4885 |
| US-20130288957-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS | IL36G, IL17A, IL6ST | SCN9A 400/4885HDAC1 2728/4885HDAC8 586/4885 |
| US-20130261050-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUB-POPULATION | SLC10A1, HAVCR2, GOT2 | SCN9A 3205/4885HDAC1 375/4885HDAC8 989/4885 |
| US-20130261134-A1 | MESYLATE SALT FORMS OF A POTENT HCV INHIBITOR | SLC10A1, HAVCR2, ABL1 | SCN9A 651/4885HDAC1 813/4885HDAC8 2445/4885 |
| US-20120135949-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | HAVCR2, EIF2AK2, SLC10A1 | SCN9A 3837/4885HDAC1 464/4885HDAC8 986/4885 |
| US-20140057928-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | SCN9A 829/4885HDAC1 289/4885HDAC8 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.